The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature
…, M Podhola, S Rejchrt, M Minarik, L Benesova… - Gastrointestinal …, 2016 - Elsevier
Background and Aims Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
has to date been recognized in only 8 families worldwide. Recently, different point …
has to date been recognized in only 8 families worldwide. Recently, different point …
[HTML][HTML] MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis
…, R Cuperkova, M Minarik, L Benesova - … Research and Practice, 2015 - hindawi.com
Pancreatic cancer is one of the most fatal malignancies with increasing incidence and high
mortality. Possibilities for early diagnosis are limited and there is currently no efficient therapy…
mortality. Possibilities for early diagnosis are limited and there is currently no efficient therapy…
[HTML][HTML] Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)–a helicobacter-opposite point
I Tacheci, R Repak, M Podhola, L Benesova… - Best Practice & …, 2021 - Elsevier
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare familial
gastric cancer syndrome with an autosomal dominant pattern of inheritance. It is characterised …
gastric cancer syndrome with an autosomal dominant pattern of inheritance. It is characterised …
[HTML][HTML] Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration …
C Salek, L Benesova, M Zavoral, V Nosek… - World journal of …, 2007 - ncbi.nlm.nih.gov
AIM: To establish an optimum combination of molecular markers resulting in best overall
diagnostic sensitivity and specificity for evaluation of suspicious pancreatic mass. METHODS: …
diagnostic sensitivity and specificity for evaluation of suspicious pancreatic mass. METHODS: …
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non …
O Fiala, M Pesek, J Finek, L Benesova, B Belsanova… - Cancer genetics, 2013 - Elsevier
The role of KRAS mutations in molecular targeted therapy by epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has not …
tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has not …
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors
L Benesova, M Minarik, D Jancarikova… - Anticancer …, 2010 - ar.iiarjournals.org
Background: Concurrent presence of EGFR and KRAS mutations in non-small cell lung
cancer (NSCLC) patients is relatively rare and their appearance is believed to be mutually …
cancer (NSCLC) patients is relatively rare and their appearance is believed to be mutually …
The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second-or third-line chemotherapy
…, M Pesek, Z Bortlicek, M Minarik, L Benesova… - Anticancer …, 2016 - ar.iiarjournals.org
Background/Aim: The prognostic and predictive value of Kirsten rat sarcoma viral oncogene
homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. …
homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. …
[HTML][HTML] Monitoring of early changes of circulating tumor DNA in the plasma of rectal cancer patients receiving neoadjuvant concomitant chemoradiotherapy …
F Pazdirek, M Minarik, L Benesova, T Halkova… - Frontiers in …, 2020 - frontiersin.org
Introduction: Patients with locally advanced rectal cancer (LARC) are undergoing neoadjuvant
chemoradiotherapy (NCRT) prior to surgery. Although in some patients the NCRT is …
chemoradiotherapy (NCRT) prior to surgery. Although in some patients the NCRT is …
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib
O Fiala, M Pesek, J Finek, L Benesova… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients
with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction …
with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction …
[HTML][HTML] Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
L Benešová, T Hálková, R Ptáčková… - World Journal of …, 2019 - ncbi.nlm.nih.gov
BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA)
detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term …
detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term …